Northern Biologics Inc., a developer of first-in-class immuno-oncology products, today announced that its lead immuno-oncology antibody, MSC-1, began clinical testing at Memorial Sloan Kettering Cancer Center with plans to soon expand to other world-leading sites in Canada and Europe.

MSC-1 is a humanized antibody against a soluble cytokine called LIF (see “About LIF” below). LIF plays a multi-faceted role in cancer, and as a result inhibiting the target opens up two therapeutic avenues: reversal of tumor immunosuppression and blockade of tumor growth via inhibition of cancer initiating cells (CICs).

You can read the full story here